Pharmaceutical Market Europe • October 2020 • 42-44
APPOINTMENTS
Moderna
DAN STANER
Moderna has appointed Dan Staner as vice president and general manager, Switzerland. Staner has over 25 years of experience in the global pharmaceutical industry, most notably with Eli Lilly. His previous leadership roles have included finance, marketing, strategy, global product development as well as general management. Staner’s previous geographic responsibilities have covered a range of locations, from Europe and the US to the Middle East, Africa and South Asia. In addition to his professional experience, Staner has an MSc in Economics and Business from HEC University of Lausanne. In his new role at Moderna, Staner will be responsible for the company’s presence and activities in Switzerland, building a team to cover a range of functions spanning medical, regulatory, pricing, reimbursement, market access, government affairs and commercial operations.
Moderna
MICHAEL MULLETTE
Moderna has also appointed Michael Mullette as managing director in Canada. Mullette joined Moderna initially in August as vice president, market access – a role he will continue to operate in. Prior to joining Moderna, he spent two years working as general manager and country chair for Sanofi Canada. Before that, he spent 19 years at Sanofi Pasteur working in progressively senior roles.
The Novo Nordisk Foundation
MARTIN RIDDERSTRÅLE
The Novo Nordisk Foundation has appointed Martin Ridderstråle as head of patient care. Currently, Ridderstråle serves as corporate vice president at Novo Nordisk A/S, where he is head of clinical pharmacology and translational medicine. Previously he spent three years as head of clinic at the Steno Diabetes Centre, Gentofte based in Denmark.
Sanofi Espoir Foundation
JEAN-CHRISTOPHE RUFIN
Jean-Christophe Rufin has been appointed as president of the Sanofi Espoir Foundation. Rufin is a French doctor, diplomat and writer, previously serving as an adviser to the Secretary of State for Human Rights between 1986-1988. He will take the helm at Sanofi Espoir, which was created in 2010 to reduce inequalities in health in France and internationally.
NovaGo Therapeutics
IAN METCALFE
Ian Metcalfe has joined NovaGo Therapeutics as its new chief executive officer. Prior to joining NovaGo, Metcalfe held roles of increasing responsibility at a number of pharmaceutical and biotech companies, including Berna Biotech, Roche, Nestlé Health Science and Corlieve Therapeutics. He has over 20 years of business experience across various industries focused on biotech and healthcare.
Tizona Therapeutics
CHRISTINE O’BRIEN
Tizona Therapeutics has appointed Christine O’Brien as its new chief executive officer. Prior to taking on the role of CEO, O’Brien worked as chief operating officer for Tizona. She initially joined the company in 2015, leading the cross-functional portfolio and operating plan. She also provided leadership for the clinical stage project teams, working with external partners on strategy and development plans.
Sensyne Health
MICHAEL MACDONNELL
Michael Macdonnell has joined Sensyne Health as chief operating officer. Prior to joining Sensyne, Macdonnell worked as director of global development at Google Health, which he joined from Google DeepMind. Prior to joining Google, he was national director of system transformation and director of strategy at NHS England, where he oversaw the delivery of key strategic initiatives.
Axol Bioscience
PHILIPPE LOPES-FERNANDES
French pharma company Ipsen has appointed Philippe Lopes-Fernandes as executive vice president and chief business officer. Prior to joining Ipsen, Lopes-Fernandes worked at Merck KGaA where he served as senior vice president, global head of business development and alliance management. Before that, he held a variety of roles at Merck KGaA in business development, mergers & acquisitions, finance and marketing.
LEO Pharma
BECKI MORISON
Danish pharma company LEO Pharma has appointed Becki Morison as executive vice president, global therapeutic & value strategy. Morison joins LEO Pharma from Eli Lilly, where she held the role of vice president, US Immunology. Prior to that, she held several leadership positions in the US and Australia, as well as in the UK and the Nordics.
ELRIG UK
MELANIE LEVERIDGE
The European Laboratory Research & Innovation Group (ELRIG) UK has appointed Melanie Leveridge as chair. Leveridge has 15 years of experience in drug discovery, laboratory automation, screening and sample management and has been an active ELRIG member since 2017. She is also head of screening, profiling and mechanistic biology UK, and global compound management at GlaxoSmithKline.
Vedanta Biosciences
JEFFREY SILBER
Vedanta Biosciences has appointed Jeffrey Silber as chief medical officer. Silber has extensive experience across multiple therapeutic areas to Vedanta, from a number of roles at Merck, AbbVie and EMD Serono. Most recently, he served as senior vice president of global development at EMD Serono and previously served as vice president of strategic portfolio development at AbbVie.
4D Pharma
KATRIN RUPALLA
4D Pharma has appointed Katrin Rupalla as an independent non-executive director. Rupalla brings over 20 years of experience in the pharmaceutical industry, as well as extensive regulatory and clinical expertise in the fields of oncology and neuroscience to 4D Pharma. She has previously served in senior positions at Merck & Co, Roche, Celgene and Bristol Myers Squibb.
Silence Therapeutics
MARK ROTHERA
Silence Therapeutics has appointed Mark Rothera as president and chief executive officer. Rothera brings more than 30 years of experience in the biopharmaceutical industry to Silence, with a record of commercial and operational leadership. Prior to joining Silence, he served as CEO of Orchard Therapeutics, and previously worked as chief commercial officer at PTC Therapeutics.
VectivBio
NADER YOUSSEF
Nader Youssef has been appointed as senior vice president and head of global clinical development and medical affairs at VectivBio. Most recently, Youssef served as vice president of clinical development at Passage Bio, and chief medical officer at Nutrinia. In addition, he has over 20 years of diverse experience in academia and the biopharmaceutical industry.
Imcyse
DENIS BEDORET
Imcyse has appointed Denis Bedoret as chief executive officer. Most recently, Bedoret was chief executive officer at MaSTherCell, which was acquired by Catalent Pharma Solutions earlier this year. Prior to his position at MaSTherCell, he served as chief operations officer at CRO company Quality Assurance. Before that, he was engagement manager at McKinsey & Company, where he focused on life sciences projects.
FibroGen
PERCY CARTER
Percy Carter has been appointed to the newly created position of chief scientific officer at FibroGen. Before joining the FibroGen team, Carter served as the global head of discovery services at Janssen, the pharmaceutical division of Johnson & Johnson. Prior to his role at Janssen, he held the role of senior vice president and head of discovery for Bristol Myers Squibb.
Immunicum
SVEN ROHMANN
Immunicum has appointed Sven Rohmann as chief executive officer. Rohmann brings 30 years of experience from biotechnology and pharmaceutical companies to the team at Immunicum, most recently working as acting CEO of Oasmia Pharmaceuticals. He also held senior managerial positions at Novartis and Merck KGaA. At Merck KGaA, he helped to build an oncology-focused product portfolio.
A+ Science
HÅKAN FRÖDERBERG
A+ Science has appointed Håkan Fröderberg as its new chief executive officer. Fröderberg has extensive experience gained from leading positions in several companies within the life sciences industry. Before joining A+, he worked at Celgene as a business unit director and was a member of the Nordic management team. Before that, he was the Nordic CEO of Nigaard Pharma.
Relief Therapeutics
GILLES DELLA CORTE
Relief Therapeutics has appointed Gilles Della Corte as chief medical officer. Prior to joining Relief, Della Corte held several senior clinical research positions at Merck Serono, and earlier in his career he also held positions of increasing responsibility at several CROs, pharmaceutical and start-up companies. This includes, Servier, Solvay Pharma and Phoenix Life Sciences.
Rewind Therapeutics
KEES BEEN
Kees Been has been appointed as non-executive director of Belgium-based biotech company Rewind Therapeutics. Been has 40 years’ experience in the biopharmaceutical industry, and is the founder, president and chief executive officer of Lysosomal Therapeutics. He was also formerly the president and CEO of EnVivo Pharmaceuticals and spent four years at Biogen, where he directed the oncology business unit.
Gyroscope Therapeutics
SEAN BOHEN
London-headquartered Gyroscope Therapeutics has appointed Sean Bohen to the board of directors. Bohen brings more than 30 years of experience in the discovery and development of new medicines to Gyroscope. Previously, he was the chief medical officer and executive vice president, global medicines development at AstraZeneca. Prior to that, he was senior vice president of Genentech Early Development.
Bedrock Group
MARIE LITTLE
Bedrock Group has appointed Marie Little as managing director of Bedrock Healthcare Communications. Previously, Little served as the managing director of OPEN Health Patient and Brand Communications and also worked as client services director at LEC, an OPEN Health company. She is set to bring a wealth of experience across brand and medical communications to the Bedrock team.
Springer Healthcare
BRYCE MCMURRAY
Bryce McMurray has been appointed vice president, medical communications at Springer Healthcare, part of the Springer Nature group. Formerly, McMurray worked as vice president of inScience Communications. He has over 25 years of experience within CRO, pharmaceutical, medical publishing and communications companies, spanning Europe, North America and Asia Pacific.
67health
JOELLA MELVILLE
67health has appointed Joella Melville as senior director. Melville has over 12 years of experience in healthcare communications from both in-house roles at pharmaceutical companies and senior consultant roles at healthcare communications agencies. Previously, she served as managing director of former independent agency Packer Forbes and as a senior director at GCI Health.
VCCP Health
SARAH VERHOEFF
VCCP Health has appointed Sarah Verhoeff as business director. Verhoeff has over 20 years of experience in advertising, with a specialisation in the healthcare sector. She has worked across dozens of therapy areas via all media channels and on a global scale. In addition, Verhoeff’s therapeutic experience is broad, including OTC products, Rx portfolios and medicals devices.
Makara Health
SHULA SARNER
Makara Health has appointed Shula Sarner as director, scientific services. Sarner joins Makara from Lucid, where she held the position of executive scientific director. She has over 18 years of medical communications experience following a successful career in academic research and biotech. Sarner has thorough knowledge of scientific and clinical processes and an understanding of healthcare professional behaviour.
Makara Health
NEIL PADGETT
Neil Padgett has also joined Makara as the agency’s new creative director. Padgett brings over 20 years of experience in leading creative healthcare campaigns at international levels. This includes a stint as managing director, creative at FCB Halesway and also as creative director at Halesway. At Makara he will lead the creative team alongside senior designer Jamie Hickton.
BMA
GREG BEALES
Doctors’ trade union BMA has appointed Greg Beales as its communications and policy director. Beales joins from Shelter, where he was director of communications, policy and campaigns. He was previously a senior Downing Street advisor to Prime Ministers Tony Blair and Gordon Brown, working across government on a range of healthcare issues.
Porterhouse Medical Group
ERICA CAVE
Porterhouse Medical Group has promoted Erica Cave to the new role of associate scientific services director. Cave is a long-standing member of Porterhouse’s scientific services team and has spent 12 years at the company so far. She also has a strong scientific background and has been instrumental in setting up the newest Porterhouse office based in Nottingham, UK.
Porterhouse Medical Group
JESSICA SALE
Also joining Porterhouse Medical Group is Jessica Sale, who has joined as an associate medical director. Prior to joining Porterhouse, Sale was a Foundation Year 2 doctor working at the University Hospitals Birmingham NHS Foundation Trust. She studied for her Bachelor of Medicine and Bachelor of Surgery (MBChB) degree at the University of Liverpool.
Porterhouse Medical Group
EMMA WATTERSON
Emma Watterson also joins Porterhouse Medical Group as an associate medical writer. Watterson has a BSc in biochemistry from the University of Birmingham, and also previously shadowed doctors at Nottingham City Hospital in the infectious disease ward and critical care unit. She is set to join Porterhouse at its new office based in Nottingham, UK.
Porterhouse Medical Group
LUKE SMITH
Rounding out the new hires at Porterhouse Medical Group is the appointment of Luke Smith, who has joined the team as an associate medical writer. Smith has a BA in English literature from the University of Warwick, as well as a BSc in biomedicine from Birkbeck University of London and has completed an MRes and a PhD at King’s College London.
Makara Health
LAURA CARSWELL
& LOUISE BAINS
Makara Health has added another two new members to its team, with the appointment of Laura Carswell as project director and Louise Bains as project manager. Carswell joins from Bedrock Healthcare Communications, where she served as an account director. Bains joins from Hospice UK, where she held the role of projects and programmes delivery executive.